An evaluation of cefaclor in Pakistani children with pharyngotonsillitis.
| Autor: | Siddiqui SJ; Eli Lilly, Indonesia., Awan A, Ekangakic A, Stocks JM, Sheikh GA, Ahmad TM, Mian FA, Kanjee S, Sheikh S, Rashid A, Yousfani AH, Talat A, Ahmad M |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | JPMA. The Journal of the Pakistan Medical Association [J Pak Med Assoc] 2002 Oct; Vol. 52 (10), pp. 451-6. |
| Abstrakt: | Objective: To assess the efficacy, safety of cefaclor for the treatment of pharyngotonsillitis in Pakistani children. Method: Pakistani children between the ages of two to twelve years and diagnosed with pharyngotonsillitis were eligible to participate in the study. Cefaclor was administered three times daily for a total dose of 20-40 mg/kg/day, depending on the severity of the infection, for 7 days. Patients were evaluated on the basis of symptomatic response and antibiotic susceptibility pattern as a result of bacteriological examination. Results: Based on observed pre-therapy signs/symptoms of infection with pharyngotonsillitis, 99% of patients (95% CI=94.9% to 100.0%) were reported as having a symptomatic response of Cure or Improvement by end of study. Group A b-haemolytic Streptococci was the most prevalent pathogen isolated pre-therapy (occurring in 45% of patients). Of all patients for whom this pathogen was isolated, 64% had complete eradication by end of therapy, while there was persistence or superinfection in 36% of patients. Only 9 occurrences of non-serious adverse events were observed among 7 of the 107 patients, including diarrhea (5), nausea (1), vomiting (1), rash (1) and stomatitis (1). Conclusion: Based on the high symptomatic response rate of 99% and the positive safety data, cefaclor was found to be effective and safe in treating Pakistani children with pharyngotonsillitis. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|